In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa

Arnold S. Bayer, Kwang Sik Kim

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of azlocillin + amikacin was compared to ciprofloxacin (with and without amikacin) in 96 rabbits with right-sided endocarditis due to Pseudomonas aeruginosa. Animals received either: (1) no therapy (controls); (2) amikacin (15 mg/kg/ day) + azlocillin (400 mg/kg/day); (3) ciprofloxacin (80 mg/kg/day) or (4) amikacin + ciprofloxacin (above dosages). All three antibiotic regimens were significantly more effective than no therapy in reducing mortality (p < 0.0005), preventing pulmonary infarction (p < 0.0005) and reducing mean vegetation titers of P. aeruginosa (p < 0.0005). Also, the three therapy regimens were equivalent in preventing bacteriologic relapse after discontinuing therapy. No development of antibiotic resistance in vivo was observed.

Original languageEnglish (US)
Pages (from-to)364-373
Number of pages10
JournalCHEMOTHERAPY
Volume32
Issue number4
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Keywords

  • Azlocillin
  • Ciprofloxacin
  • Experimental endocarditis
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this